Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent steps he has taken to help improve (a) recognition (b) early intervention and (c) access to treatment for patients who experience Postpartum haemorrhage.

Answered by Preet Kaur Gill

While data is not available for Slough alone, in 2025, there were 280 reported cases of postpartum haemorrhage of 1,500 millilitres or more at the Frimley Health NHS Foundation Trust, which serves patients in Slough and the wider area.

Annual trust data on reported postpartum haemorrhages of 1,500 millilitres or more between 2022 and 2025 is available at the following link:

https://digital.nhs.uk/dashboards/maternity-and-neonatal-equalities-dashboard

The reported data may not represent all postpartum haemorrhages of 1,500 millilitres or more due to variations in data quality between trusts and over time. Monthly data back to April 2019, including more detailed information on data quality, is available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/maternity-services-monthly-statistics

To tackle leading causes of maternal mortality and morbidity, we have launched a Maternal Care Bundle to set clear standards across all services, focused on the main causes of maternal death and harm. It will codify best practice already in use and support more consistent care, and we expect it to help reduce deaths and serious harm, especially among higher-risk groups, as well as reduce inequalities in maternal mortality.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many instances of postpartum haemorrhage occurred in Slough constituency in each of the last five years.

Answered by Preet Kaur Gill

While data is not available for Slough alone, in 2025, there were 280 reported cases of postpartum haemorrhage of 1,500 millilitres or more at the Frimley Health NHS Foundation Trust, which serves patients in Slough and the wider area.

Annual trust data on reported postpartum haemorrhages of 1,500 millilitres or more between 2022 and 2025 is available at the following link:

https://digital.nhs.uk/dashboards/maternity-and-neonatal-equalities-dashboard

The reported data may not represent all postpartum haemorrhages of 1,500 millilitres or more due to variations in data quality between trusts and over time. Monthly data back to April 2019, including more detailed information on data quality, is available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/maternity-services-monthly-statistics

To tackle leading causes of maternal mortality and morbidity, we have launched a Maternal Care Bundle to set clear standards across all services, focused on the main causes of maternal death and harm. It will codify best practice already in use and support more consistent care, and we expect it to help reduce deaths and serious harm, especially among higher-risk groups, as well as reduce inequalities in maternal mortality.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has undertaken an assessment of the funding required to achieve the aims set out in the interim update to the Modern Service Framework for Palliative and End of Life.

Answered by Stephen Kinnock - Secretary of State for Wales

The Modern Service Framework for Palliative Care and End-of-Life Care was never intended to introduce new, ring‑fenced funding. Its primary purpose is to set the strategic direction for improving palliative care and end-of-life care, including reducing variation in access, quality, and outcomes across the system.

In the context of wider fiscal pressures, the focus is on ensuring that existing resources are used as effectively as possible, supported by a shift towards more strategic, population‑based commissioning.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of recent findings by UCL, City St George’s and Carers Trust that young adult carers are more than twice as likely as non-carers to be 'Persistently NEET' for two years or more.

Answered by Stephen Kinnock - Secretary of State for Wales

The Government recognises the valuable contribution of unpaid carers, including young adult carers, and the challenges that caring responsibilities can present for education, training, and employment.

The Department has noted the recent research by University College London City St George’s and the Carers Trust, which contributes to the evidence base and will inform policy development. The Government continues to work across departments to support unpaid carers, including young adult carers, to access the support they need to balance caring responsibilities with education, employment, and their own health and wellbeing.

On 14 July 2026, the Government published the Cross-Government Action Plan for Unpaid Carers, setting out measures to improve recognition of unpaid carers, connect them with the right support, and help them balance caring with work, education, health, and everyday life.

The Government is also committed to improving opportunities for young people to access education, training, and employment. Through the Youth Guarantee and wider skills and employment reforms, the Government is investing £2.5 billion over the next three years to support young people into opportunities to learn and earn.

The Government will continue to review the evidence, including this research, as it develops policies to improve outcomes for unpaid carers and young people.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many agency staff were employed by his Department in each of the last five years.

Answered by Stephen Kinnock - Secretary of State for Wales

Information on the Department’s workforce is published monthly on the GOV.UK website, and can be found at the following link:

https://www.gov.uk/government/collections/dhsc-workforce-management-information

The following table shows the number of non-payroll staff recorded in the relevant Monthly Workforce Management Information categories for the Department, in line with published Monthly Workforce Management Information and excluding agencies, at the end of March in each of the last five years:

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether additional recurrent funding will be provided alongside implementation of the proposed NHS dental contract reforms.

Answered by Stephen Kinnock - Secretary of State for Wales

We are committed to reforming the dental contract by the end of this Parliament, with a focus on matching resources to need, improving access, promoting prevention, and rewarding dentists fairly, while enabling the whole dental team to work to the top of their capability.

The financial pressures and the cost of new commitments for the National Health Service are analysed as part of the Spending Review process. The 2025 Spending Review sets departmental budgets for day-to-day spending up to 2028/29 and for capital for five years to 2029/30. This level of funding growth is intended to support the NHS in delivering the Government’s priorities, including commitments set out in the Government’s Plan for Change. Further detail is provided at the following link:

https://www.gov.uk/government/publications/spending-review-2025-document/spending-review-2025-html

The Government has committed to hold a Spending Review every two years. The process for the next Spending Review, due to be held in 2027, will be set in due course.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of access to social care services for the elderly.

Answered by Stephen Kinnock - Secretary of State for Wales

In England, under the Care Act 2014, local authorities have a duty to meet the eligible needs of the people in their area including the elderly.

Local authorities in England are also tasked with the duty to shape their care markets to meet the diverse needs of all local people. This includes commissioning a diverse range of care and support services that enable people to access quality care.

The Care Quality Commission (CQC) is assessing how well local authorities in England are delivering adult social care, specifically how local authorities are performing against their duties under Part 1 of the Care Act 2014. All reports and ratings are published on the CQC’s website.

The Government is making over £4.6 billion of additional funding available in England for adult social care in 2028/29 compared to 2025/26, to support the sector in making improvements.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what estimate he has made of the volume of preventable deaths in the UK due to respiratory diseases; and what steps he plans to take to address this.

Answered by Sharon Hodgson

Data held for England shows that in 2024 there were 9,609 deaths in people aged under 75 years old where the death was due to respiratory disease and considered preventable. This data is available at the following link:

https://fingertips.phe.org.uk/profile/respiratory-disease/data

Smoking remains the leading preventable cause of respiratory disease and respiratory death. The landmark Tobacco and Vapes Act will help deliver our ambition for a smoke-free United Kingdom.

The Government is also improving access to earlier diagnosis of respiratory disease through community diagnostic centres, helping more people to access respiratory testing closer to home.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the forthcoming Modern Service Framework for Dementia and Frailty will (a) improve the quality and consistency of dementia data and (b) improve data capture on dementia at the local level.

Answered by Stephen Kinnock - Secretary of State for Wales

We are considering all options to help reduce waiting times and improve dementia diagnosis and care, including reviewing targets, metrics, and data.

We are engaging with a wide group of partners to understand what should be included to ensure the best outcomes for people living with frailty and dementia, and as part of this exercise, we will develop a list of best evidenced interventions following analysis of the evidence gathering exercise submissions and wider research.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of (a) introducing a maximum annual limit on the amount of public funding that may be spent on an individual's adult social care package and (b) implementing a cap on annual local authority expenditure on adult social care.

Answered by Stephen Kinnock - Secretary of State for Wales

No assessment has been made of either introducing a maximum annual limit on the amount of public funding that may be spent on an individual’s adult social care package, or implementing a cap on annual local authority expenditure on adult social care.

Under the Care Act 2014, access to care and support is based on a person's eligible needs, while any contribution towards the cost of that care is based on what they can afford to pay.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that NHS weight management services support long-term weight maintenance.

Answered by Sharon Hodgson

Supporting people to achieve and maintain weight loss over the long term is a core principle of National Health Service weight management services. National, integrated care board, and local authority commissioned services combine behavioural support, healthier eating, physical activity, and relapse prevention to help people sustain weight loss and improve their long-term health.

Nationally commissioned services, such as the NHS Digital Weight Management Programme and the suite of Healthier You programmes, such as the NHS Behavioural Support for Obesity Prescribing, the NHS Diabetes Prevention Programme, and the NHS Type 2 Diabetes Path to Remission, all place a strong emphasis on supporting long term weight maintenance. These services are designed not only to help people achieve and sustain weight loss and a healthy weight, but also to prevent, improve, or manage obesity related long-term conditions, including reducing the risk of developing type 2 diabetes and supporting remission for those already living with the condition.

The NHS continues to evaluate and develop its weight management services to ensure they reflect the latest clinical evidence and support people to achieve sustainable improvements in their health and reduce future demand on NHS services.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many women's health hubs have been established in NHS Devon ICB; and what services they provide.

Answered by Sharon Hodgson

NHS Devon Integrated Care Board developed a variation of the women’s health hub model, focused on virtual and system-wide provision for local women. More information about this is available on the One Devon website at the following link:

https://onedevon.org.uk/our-work/services-and-support/womens-health-strategy/

The Devon Women’s Health Hubs project has two main priorities:

• developing a range of virtual services along the menopause pathway, to ensure women receive the right advice and guidance at the point of care; and

• enhancing provision of Long-Acting Reversible Contraception, for both contraceptive and non-contraceptive reasons such as heavy menstrual bleeding.

While Devon does not yet have a physical hub, the long-term ambition remains to work towards establishing one in the South West. This will include exploring how neighbourhood and place-based settings could support its development.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department plans to publish data on the performance of local obesity services, including service coverage, waiting times, and patient outcomes split by age, gender, ethnicity and socio-economic status.

Answered by Sharon Hodgson

NHS England has established the National Obesity Audit (NOA) to improve understanding of weight management services across England. The audit analyses data collected from hospitals, community settings, and general practices on weight management services and interventions commissioned, or funded, by local authorities and the National Health Service. The NOA currently publishes information on specialist weight management services and bariatric surgery and is continuing to work towards a comprehensive picture of obesity care, including service access, outcomes, and inequalities, to support service improvement and development.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 July 2026 to Question 15320 on Folic Acid, with reference to the Food Standard Agency's information page entitled Guidance: Folic Acid, updated on 10 July 2026, where the nine pieces of evidence can be found as the links are not working.

Answered by Sharon Hodgson

The Food Standards Agency’s (FSA) website moved over to the GOV.UK platform on 25 June 2026. The FSA’s information page on the fortification of flour with folic acid is available at the following link:

https://www.gov.uk/government/publications/folic-acid/folic-acid

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effectiveness of the policy under which women are routinely offered specialist recurrent miscarriage care after three pregnancy losses.

Answered by Preet Kaur Gill

We recognise that miscarriage can have a devastating impact on women and their families, and we are determined that they receive the support they need. That is why we have committed, in the Renewed Women’s Health Strategy, to closely reviewing the findings presented in the Tommy’s Graded Model of Care study, as part of our broader work on miscarriage care.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to improve health outcomes for people living with COPD.

Answered by Sharon Hodgson

To enable faster diagnosis of chronic obstructive pulmonary disease (COPD) and earlier access to treatment, access to spirometry tests in community diagnostic centres is growing and will continue to do so as more sites come online.

Pulmonary rehabilitation is a key intervention to improve the health of people with COPD. NHS England has published commissioning standards for pulmonary rehabilitation and COPD, setting out the benchmarks for high-quality services. This includes reducing health inequalities and ensuring equitable access.

In addition, smoking is the number one preventable cause of COPD. The landmark Tobacco and Vapes Act will help deliver our ambition for a smoke-free United Kingdom.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the forthcoming Modern Service Framework for Palliative and End of Life Care will be accompanied by a costed delivery plan.

Answered by Stephen Kinnock - Secretary of State for Wales

The forthcoming Modern Service Framework (MSF) for Palliative Care and End-of-Life Care will include a delivery plan to support implementation of the framework. On 4 June, we published an interim update in the form of a Written Ministerial Statement, which is available at the following link:

https://questions-statements.parliament.uk/written-statements/detail/2026-06-04/hcws88

The MSF will support the shift to the strategic commissioning of palliative care and end of life care, based on the integrated needs assessment completed by the integrated care board. This supports the effective and equitable use of resources of services commissioned and contracted at a local level to meet identified population needs now and in the future.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the speech by Baroness Merron on 3 March 2026 on the proposed retail licensing scheme for tobacco, vaping and nicotine products, Official Report, House of Lords, columns 1169 to 1171, when he plans to consult on that scheme; and what assessment his Department has made of the implications for the enforcement of restrictions on the packaging, appearance and retail display of vaping and nicotine products.

Answered by Sharon Hodgson

On 10 July, we launched a United Kingdom-wide consultation on new proposals to restrict tobacco, vape, and nicotine product packaging, flavour descriptors, device appearance, and changing where and how vapes and nicotine products are displayed in shops. Enforcement authorities will be able to take proportionate enforcement action against non-compliance with future regulations made under the Tobacco and Vapes Act 2026.

A future retail licensing scheme for tobacco, vapes, and nicotine products will strengthen enforcement and support law-abiding retailers, while tackling those who break the law. Those found to be in breach of a condition of their licence, or other statutory requirements, could face potential licence revocation. Whilst the specific grounds on which a licence may be granted, suspended, revoked, or varied will be subject to consultation, we want to ensure retailers are operating responsibly and in line with legal requirements.

We intend to consult on our proposals for a retail licensing scheme for tobacco, vapes, and nicotine products in 2027.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 June 2026 to Question 9319, if he will ensure that guidance on the Tobacco and Vapes Act 2026 is published with sufficient time for retailers to understand and prepare for their obligations; and what engagement his Department has had with retailers on this matter.

Answered by Sharon Hodgson

We plan to publish guidance on the Tobacco and Vapes Act shortly which will give significant time for retailers to understand and prepare for their obligations.

The Department has been engaging with representative bodies, including the Association of Convenience Stores and the British Retail Consortium, and will continue to engage with them on this matter.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the NHS Liver Transformation Programme reduces health inequalities in liver disease outcomes for people living in areas with high levels of deprivation.

Answered by Sharon Hodgson

The resource for transforming liver services sits with integrated care boards, who will consider local need and the actions to progress alongside other clinical priorities.

The national team’s role has been to bring together relevant stakeholders to co-ordinate, influence and share learning to support local transformation.

NHS England has identified Clinical and Programme oversight resource to be active during reorganisation, with a lead programme management resource to support prioritised national workstreams.

The programme to date has prioritised reviews of the differential impact of liver disease in relation to health inequalities and deprivation. Examples include evidence of liver-related premature mortality being 4.8 times higher in the most deprived areas, 86% of liver disease deaths, which have increased by 400% since 1970, being related to alcohol harms, South Asian communities being at a higher risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis, and type 2 diabetes and MASLD disproportionately affecting the most deprived communities.

The transformation of the liver services programme includes a number of workstreams including awareness, early identification, and treatment of liver disease, and these will benefit people in these communities. Geographically specific data is available to local commissioners to assist them with focusing their work on deprivation and inequalities, to support their prioritisation.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the NHS Liver Transformation Programme is adequately staffed and prioritised during the ongoing reorganisation of NHS England.

Answered by Sharon Hodgson

The resource for transforming liver services sits with integrated care boards, who will consider local need and the actions to progress alongside other clinical priorities.

The national team’s role has been to bring together relevant stakeholders to co-ordinate, influence and share learning to support local transformation.

NHS England has identified Clinical and Programme oversight resource to be active during reorganisation, with a lead programme management resource to support prioritised national workstreams.

The programme to date has prioritised reviews of the differential impact of liver disease in relation to health inequalities and deprivation. Examples include evidence of liver-related premature mortality being 4.8 times higher in the most deprived areas, 86% of liver disease deaths, which have increased by 400% since 1970, being related to alcohol harms, South Asian communities being at a higher risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis, and type 2 diabetes and MASLD disproportionately affecting the most deprived communities.

The transformation of the liver services programme includes a number of workstreams including awareness, early identification, and treatment of liver disease, and these will benefit people in these communities. Geographically specific data is available to local commissioners to assist them with focusing their work on deprivation and inequalities, to support their prioritisation.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what funding has been allocated to the NHS Liver Transformation Programme for 2026-27.

Answered by Sharon Hodgson

The resource for transforming liver services sits with integrated care boards, who will consider local need and the actions to progress alongside other clinical priorities.

The national team’s role has been to bring together relevant stakeholders to co-ordinate, influence and share learning to support local transformation.

NHS England has identified Clinical and Programme oversight resource to be active during reorganisation, with a lead programme management resource to support prioritised national workstreams.

The programme to date has prioritised reviews of the differential impact of liver disease in relation to health inequalities and deprivation. Examples include evidence of liver-related premature mortality being 4.8 times higher in the most deprived areas, 86% of liver disease deaths, which have increased by 400% since 1970, being related to alcohol harms, South Asian communities being at a higher risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis, and type 2 diabetes and MASLD disproportionately affecting the most deprived communities.

The transformation of the liver services programme includes a number of workstreams including awareness, early identification, and treatment of liver disease, and these will benefit people in these communities. Geographically specific data is available to local commissioners to assist them with focusing their work on deprivation and inequalities, to support their prioritisation.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the volume of preventable deaths in the UK due to respiratory diseases.

Answered by Sharon Hodgson

Data held for England shows that in 2024 there were 9,609 deaths in people aged under 75 years old where the death was due to respiratory disease and considered preventable. This data is available at the following link:

https://fingertips.phe.org.uk/profile/respiratory-disease/data

Smoking remains the leading preventable cause of respiratory disease and respiratory death. The landmark Tobacco and Vapes Act will help deliver our ambition for a smoke-free United Kingdom.

The Government is also improving access to earlier diagnosis of respiratory disease through community diagnostic centres, helping more people to access respiratory testing closer to home.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of introducing a dual-tier NHS Right to Choose Tariff for ADHD and autism assessments that distinguishes between straightforward and complex cases.

Answered by Preet Kaur Gill

The 2026/27 NHS Payment Scheme was published on 26 March 2026 and came into effect from 1 April 2026. The scheme governs transactions between providers and commissioners of secondary healthcare. The attention deficit hyperactivity disorder (ADHD) and autism payment guidance has also been updated and sets out national expectations for ADHD and autism services. This guidance is primarily intended for finance, costing, and data teams working in ADHD and autism assessment services, and integrated care boards (ICBs) with commissioning responsibilities for these services. The purpose is to support commissioners and providers to build consistent, transparent, and equitable ADHD and autism diagnostic pathways, with clear data requirements and a shared understanding of what good looks like.

Guide prices for ADHD and autism assessments were published as part of the 2026/27 NHS Payment Scheme. NHS England is engaging on the use of these prices and how they could be developed further, including whether to differentiate between straightforward and complex cases. The current prices already include a separate price for patients receiving a combined assessment for ADHD and autism which is often provided to more complex patients.

NHS England is continuing work on pricing arrangements for autism and ADHD assessment services through the NHS Payment Scheme. This aims to support a more equitable and consistent approach to commissioning and service delivery.

The Government announced on 4 December 2025 the launch of an Independent Review into Prevalence and Support for Mental Health Conditions, ADHD and Autism. The final report, due in the summer, will make recommendations on how the Government, the health system, and wider public services can respond to increasing demand for support more fairly and effectively so that people receive the right support, at the right time, in the right place. The next stage of the review will look at service design and how services might respond more effectively to rising need, including the role of earlier intervention, community-based provision, and more integrated pathways across health, education, and other public services. The review will also look at the question of what role the private sector plays in diagnostic services.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has made an estimate of the number of FTE GPs at surgeries in Castle Point constituency over each of the next five years.

Answered by Stephen Kinnock - Secretary of State for Wales

As independent businesses that hold contracts with the National Health Service, practices determine the staffing skill mix to best suit the patients they serve. GP services are commissioned and assured by integrated care boards to meet the needs of changing populations and demographics.

Total full-time equivalent GPs in Castle Point constituency have increased in the past five years, from 31.37 in May 2022 to 41.58 in May 2026.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of using the NHS Lung Cancer Screening Programme to improve the earlier diagnosis of chronic respiratory diseases, including COPD.

Answered by Sharon Hodgson

The NHS Lung Cancer Screening Programme is designed to detect lung cancer at an earlier stage in people at high risk of developing the disease.

The Government is advised on all screening matters by the independent UK National Screening Committee (UK NSC). At its most recent review in June 2022, the UK NSC recommended targeted lung cancer screening for people aged 55 to 74 years old who are at high risk of developing lung cancer. The modelling that informed this recommendation did not include chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD).

NHS England has introduced a national Incidental Findings Protocol to ensure clinically significant incidental findings are referred for appropriate investigation and follow-up through established National Health Service pathways.

In April 2026, the UK NSC concluded a three-month public consultation on screening for COPD. The outcome of this consultation will be published in due course. In addition, the UK NSC's annual open call for new evidence and proposals for screening programmes is currently open until 30 September 2026, providing an opportunity for individuals and organisations to submit proposals supported by evidence.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of heatwaves on demand for NHS services.

Answered by Sharon Hodgson

A cross-Government collaboration, which includes the National Health Service and the Department, produces an annual Adverse Weather and Health Plan that incorporates heatwave preparedness measures. Services are expected to be prepared for periods of hot weather from 1 June to mid-September each year

NHS England recognises that extreme heat is now predicted to be a routine seasonal risk, rather than an exceptional event, and is committed to sharing key learnings from the recent period of hot weather to help further mitigate against any challenges.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the annual cost to the NHS of illnesses attributable to extreme heat.

Answered by Sharon Hodgson

A cross-Government collaboration, which includes the National Health Service and the Department, produces an annual Adverse Weather and Health Plan that incorporates heatwave preparedness measures. Services are expected to be prepared for periods of hot weather from 1 June to mid-September each year.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the availability of early intervention and treatment pathways for children with Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS); and what steps he is taking to improve access to timely diagnosis and treatment.

Answered by Preet Kaur Gill

Paediatric acute-onset neuropsychiatric syndrome (PANS) and paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) are distressing conditions for children, young people, and their families, and we recognise the challenges that families face.

The Department acknowledges the importance of raising awareness of PANS/PANDAS to improve diagnosis. That is why we welcome the formation of the PANS PANDAS Steering Group which includes representatives from key royal colleges, specialist clinical bodies, and the national charity PANS PANDAS UK. The steering group has already taken action to improve awareness, understanding, and care.

Work is underway to develop the first United Kingdom clinical guidelines for PANS and PANDAS, led by a multidisciplinary group and supported by the Royal College of Paediatrics and Child Health. These guidelines are expected to be published in autumn 2026 and will support more consistent care across the system. Pending publication, the PANS PANDAS Steering Group recommends that clinicians be aware of existing international peer-reviewed guidelines, including the PANS research consortium treatment guidelines, published in 2017, and the clinical guidance for diagnosis and management of PANS in the Nordic Countries, published in 2021.

With the backing of NHS England, a dedicated PANS PANDAS research group is advancing efforts to strengthen the evidence base, including through a nationwide surveillance study, designed to identify the number of children and young people presenting to healthcare professionals with symptoms matching the diagnostic criteria for PANS and PANDAS.

In addition, a cross-sector group is developing practical guidance for local authorities to improve support for children and young people living with PANS and PANDAS. Publication is due later this year, ensuring more consistent access to appropriate educational and social care services.

More widely, healthcare professionals are responsible for ensuring their own clinical knowledge remains up-to-date and for identifying learning needs as part of their continuing professional development. This includes taking account of new research and developments in guidance, such as that produced by the National Institute for Health and Care Excellence, to ensure that they can continue to provide high quality care to all patients.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of the level of clinical awareness and training on Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) among NHS professionals; and what steps he is taking to reduce variations in diagnosis and care.

Answered by Preet Kaur Gill

Paediatric acute-onset neuropsychiatric syndrome (PANS) and paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) are distressing conditions for children, young people, and their families, and we recognise the challenges that families face.

The Department acknowledges the importance of raising awareness of PANS/PANDAS to improve diagnosis. That is why we welcome the formation of the PANS PANDAS Steering Group which includes representatives from key royal colleges, specialist clinical bodies, and the national charity PANS PANDAS UK. The steering group has already taken action to improve awareness, understanding, and care.

Work is underway to develop the first United Kingdom clinical guidelines for PANS and PANDAS, led by a multidisciplinary group and supported by the Royal College of Paediatrics and Child Health. These guidelines are expected to be published in autumn 2026 and will support more consistent care across the system. Pending publication, the PANS PANDAS Steering Group recommends that clinicians be aware of existing international peer-reviewed guidelines, including the PANS research consortium treatment guidelines, published in 2017, and the clinical guidance for diagnosis and management of PANS in the Nordic Countries, published in 2021.

With the backing of NHS England, a dedicated PANS PANDAS research group is advancing efforts to strengthen the evidence base, including through a nationwide surveillance study, designed to identify the number of children and young people presenting to healthcare professionals with symptoms matching the diagnostic criteria for PANS and PANDAS.

In addition, a cross-sector group is developing practical guidance for local authorities to improve support for children and young people living with PANS and PANDAS. Publication is due later this year, ensuring more consistent access to appropriate educational and social care services.

More widely, healthcare professionals are responsible for ensuring their own clinical knowledge remains up-to-date and for identifying learning needs as part of their continuing professional development. This includes taking account of new research and developments in guidance, such as that produced by the National Institute for Health and Care Excellence, to ensure that they can continue to provide high quality care to all patients.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of occupational therapist prescribing rights on (a) reducing waiting times and (b) improving access to care in West Dorset.

Answered by Preet Kaur Gill

We support the expansion of non-medical professional groups being able to use legal mechanisms to prescribe, supply, and administer medicines to patients where it is safe to do so. There is a robust process in place for making such changes to ensure they are safe and beneficial for patients.

We are considering requests for the extension of existing medicines responsibilities and recently concluded a consultation on proposals to extend the medicines responsibilities of four professions. Further information can be found at the following link:

www.gov.uk/government/consultations/extend-medicines-responsibilities-for-allied-health-professions

No specific assessment has been made of the impact of extending prescribing rights for occupational therapists on patient access to treatment, waiting times, or access to care in West Dorset.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support occupational therapists to undertake training required for independent prescribing qualifications.

Answered by Preet Kaur Gill

We support the expansion of non-medical professional groups being able to use legal mechanisms to prescribe, supply, and administer medicines to patients where it is safe to do so. There is a robust process in place for making such changes to ensure they are safe and beneficial for patients.

We are considering requests for the extension of existing medicines responsibilities and recently concluded a consultation on proposals to extend the medicines responsibilities of four professions. Further information can be found at the following link:

www.gov.uk/government/consultations/extend-medicines-responsibilities-for-allied-health-professions

No specific assessment has been made of the impact of extending prescribing rights for occupational therapists on patient access to treatment, waiting times, or access to care in West Dorset.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of extending prescribing rights for occupational therapists on patient access to treatment.

Answered by Preet Kaur Gill

We support the expansion of non-medical professional groups being able to use legal mechanisms to prescribe, supply, and administer medicines to patients where it is safe to do so. There is a robust process in place for making such changes to ensure they are safe and beneficial for patients.

We are considering requests for the extension of existing medicines responsibilities and recently concluded a consultation on proposals to extend the medicines responsibilities of four professions. Further information can be found at the following link:

www.gov.uk/government/consultations/extend-medicines-responsibilities-for-allied-health-professions

No specific assessment has been made of the impact of extending prescribing rights for occupational therapists on patient access to treatment, waiting times, or access to care in West Dorset.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment has been made of the adequacy of the Care Quality Commission's enforcement powers to ensure patient safety.

Answered by Preet Kaur Gill

The Care Quality Commission (CQC) is the independent regulator of health and adult social care in England, with a range of enforcement powers. The Department holds the CQC to account regularly for its overall performance and delivery of its regulatory functions.

Under the Health and Social Care Act 2008, the CQC has civil and criminal enforcement powers enabling it to protect the public and hold registered providers and managers to account where fundamental standards are not met, or regulated activities are provided without CQC registration. Civil powers focus on reducing risks to people using services, while criminal powers enable the CQC to take action in response to serious failures. In some cases, the CQC may use both types of enforcement action.

Decisions on enforcement action are a matter for the CQC, exercised in line with its statutory remit and published enforcement policy.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent steps have been taken to reduce waiting times for ADHD assessments in the constituency of Slough.

Answered by Preet Kaur Gill

We recognise that, nationally, demand for attention deficit hyperactivity disorder (ADHD) assessments has grown significantly in recent years and that people are experiencing severe delays in accessing such services.

It is the responsibility of integrated care boards (ICBs) in England to make appropriate provision to meet the health and care needs of their local population, including providing access to ADHD assessment services. The Medium-Term Planning Framework, published 24 October 2025, was explicit that ICBs and providers are expected to optimise existing resources to reduce long waits for ADHD assessments and improve the quality of assessments by implementing existing and new guidance, as published.

The Thames Valley ICB and the Berkshire Healthcare NHS Foundation Trust have undertaken work to improve ADHD services in Slough and East Berkshire. This includes redesigning referral and triage pathways, increasing assessment capacity through additional commissioned providers, introducing digital support and self-management tools, and improving the information and support available to families. A wider transformation programme is also underway across Thames Valley to improve the consistency and quality of assessment pathways, provide support before, during, and after assessment, and strengthen collaboration between health, education, local authorities, and voluntary organisations. The programme aims to reduce waiting times, improve patient experience, and ensure people can access support based on need, rather than diagnosis alone.

The Government announced on 4 December 2025 the launch of an Independent Review into Prevalence and Support for Mental Health Conditions, ADHD and Autism. The final report, due in the summer, will inform our new approach, so people receive the right support, at the right time and in the right place. The review’s interim report, published at the end of March, sets out the evidence reviewed so far on prevalence, describes the impact of rising demand for diagnosis and support, identifies where the evidence is uncertain, and outlines the key questions for the next phase.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce waiting times for children and young people referred to Child and Adolescent Mental Health Services in the Lewes constituency.

Answered by Preet Kaur Gill

The Government recognises that, for children and young people experiencing mental health difficulties, timely access to high-quality support is essential.

The 10-Year Health Plan sets out ambitious plans to improve mental health services across the country, including for children and young people in the Lewes constituency. More widely, as prioritised in our Medium-Term Planning Framework, we are taking action to reduce the longest waits for specialist mental health support, tackle regional disparities, expand access and improve productivity across services.

Integrated care boards are responsible for commissioning children and young people's mental health services for their local populations, including in the Lewes constituency, and for ensuring services meet local needs.

We are also improving community mental health support by accelerating the rollout of Mental Health Support Teams in schools and colleges to achieve full national coverage by 2029, alongside continued investment in Early Support Hubs to help more children and young people access support before they reach crisis point.

In addition, the Government is developing a new Mental Health Strategy for England, which will set out our plans to improve access to services and support better mental health outcomes.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many cybersecurity vulnerabilities affecting medical devices have been reported to the Medicines and Healthcare products Regulatory Agency in each of the last three years.

Answered by Preet Kaur Gill

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses available data, including from the Yellow Card scheme, and seeks advice from their independent advisory committee, the Commission on Human Medicines, where appropriate to inform regulatory decisions.

The presence of a report on the adverse incident database does not necessarily demonstrate a causal relationship between the device and the event reported. The reported event may be attributable to patient, user, or other factors. As such, the data should not be regarded as a summary of confirmed adverse reactions to the device and should be interpreted with caution.

Adverse incidents are classified using the terminology developed by the International Medical Device Regulators Forum (IMDRF), with further information available at the following link:

https://www.imdrf.org/

This provides a standardised approach to coding information, including medical device malfunctions and patient or user outcomes. Annex A of the IMDRF coding system contains the codes used to describe medical device problems and malfunctions reported in adverse incident reports, with further information available at the following link:

https://www.imdrf.org/working-groups/adverse-event-terminology/annex-medical-device-problem

The following table shows the number of Yellow Card reports reporting IMDRF Annex A code A1105 – Computer System Security Problem in 2024, 2025, and 2026 until 14 July:

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of NHS dental funding levels on the recruitment and retention of dentists providing NHS care.

Answered by Stephen Kinnock - Secretary of State for Wales

Since July 2024, the Government has been rebuilding a broken National Health Service dentistry system. We have delivered 1.8 million more dental treatments and reduced the underspend from £392 million in 2023/24 to just £36 million in 2024/25, maximising the treatments provided for taxpayers’ money.

We have brought into force a package of reforms this year to address some of the most pressing issues that dentists and dental teams have been experiencing, including rewarding them more fairly for treating patients with urgent and complex needs.

Strengthening the workforce is key to our ambitions to rebuild NHS dentistry. We are increasing the supply of dentists through a sustained expansion of 50 new dental school places and an increase in exams to allow 2,000 more internationally qualified dentists to practise in the United Kingdom.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how much his department spent on research into improving the (a) accessibility and (b) cost of dentistry in the last 12 months for which data is available.

Answered by Preet Kaur Gill

The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR funds clinical, public health, and social care research and works in partnership with the National Health Service, universities, local government, other research funders, patients, and the public, and has funded a range of investigative studies, including for dentistry. In the last 12 months, the Department, via the NIHR, has spent at least £9.1 million on many aspects of dental research including improving access for vulnerable populations and assessing the cost-effectiveness of preventative and workforce-led interventions. Further information about the awards can be found at the following link:

https://fundingawards.nihr.ac.uk/?query=dentistry

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps the MHRA intends to take to consider patient and bereaved family lived experience as part of its current scientific review of Clozapine; and whether he is taking steps to ensure that lived experience actively shapes the committee's clinical determinations before key regulatory decisions have been made.

Answered by Preet Kaur Gill

The Medicines and Healthcare products Regulatory Agency (MHRA) confirms that in June 2026, the Neurology, Pain and Psychiatry Expert Advisory Group (NPPEAG) considered an assessment of clozapine drug level monitoring. The NPPEAG provided advice about the requirements for this type of monitoring. At present, clozapine drug-level monitoring is required only in specific clinical situations, partly because of the high level of variability between patients. The MHRA is taking forward the NPPEAG’s recommendations and will communicate to healthcare professionals once the regulatory position is finalised.

The review of clozapine drug-level monitoring focused on clinical and scientific data to establish the value of this type of monitoring in clinical practice. It took into account a range of information, including overall reporting patterns and themes in reports received through the Yellow Card scheme, but did not include clinical review of individual Yellow Card reports. MHRA safety assessments may also consider the views of patients and other stakeholders.

The MHRA will be launching a survey in the summer to gather information on awareness of key risks associated with clozapine, and to assess whether additional measures would be helpful for patients, their families, and carers, as well as healthcare professionals involved in the care of patients receiving clozapine.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what is the average wait time for an ADHD assessment in the Lewes constituency.

Answered by Preet Kaur Gill

Data for the number of open referrals that may be for an attention deficit hyperactivity disorder assessment is published nationally and disaggregated by integrated care board (ICB) and covers how long referrals have been open across several time periods, although it does not include an average wait time.

For the figures for the NHS Surrey and Sussex ICB please see the latest ADHD Management Information publication at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/mi-adhd/may-2026

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the Yellow Card adverse drug reaction reference GB-MHRA-MED-202605220730230940-NSQYR (linked to case file CEC 256289) is being actively reviewed by the clinical assessors of the Neurology, Pain and Psychiatry Expert Advisory Group as part of their current, ongoing safety review into clozapine drug-level monitoring for toxicity.

Answered by Preet Kaur Gill

The Medicines and Healthcare products Regulatory Agency (MHRA) confirms that in June 2026, the Neurology, Pain and Psychiatry Expert Advisory Group (NPPEAG) considered an assessment of clozapine drug level monitoring. The NPPEAG provided advice about the requirements for this type of monitoring. At present, clozapine drug-level monitoring is required only in specific clinical situations, partly because of the high level of variability between patients. The MHRA is taking forward the NPPEAG’s recommendations and will communicate to healthcare professionals once the regulatory position is finalised.

The review of clozapine drug-level monitoring focused on clinical and scientific data to establish the value of this type of monitoring in clinical practice. It took into account a range of information, including overall reporting patterns and themes in reports received through the Yellow Card scheme, but did not include clinical review of individual Yellow Card reports. MHRA safety assessments may also consider the views of patients and other stakeholders.

The MHRA will be launching a survey in the summer to gather information on awareness of key risks associated with clozapine, and to assess whether additional measures would be helpful for patients, their families, and carers, as well as healthcare professionals involved in the care of patients receiving clozapine.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what guidance exists for NHS providers on the timely communication of significant diagnostic findings to patients and their families where deterioration or recurrence of cancer is suspected.

Answered by Sharon Hodgson

While no specific assessment has been made of diagnostic imaging turnaround time guidance and the needs of patients with a recognised terminal diagnosis or the impact of separate reporting time standards, the Government is committed to reducing waiting times for all patients and expects providers to communicate findings in a compassionate manner.

NHS England has established diagnostic reporting turnaround time guidance that applies to all patients. For diagnostic imaging tests, including computed tomography and magnetic resonance imaging scans, the guidance states that verified reports should be available within four weeks of image acquisition. Performance against turnaround times is monitored through routine national reporting. In addition, cancer pathways are supported by national cancer waiting time standards, including the Faster Diagnosis Standard, which aims to ensure that patients receive a diagnosis or have cancer ruled out promptly following an urgent suspected cancer referral. The Faster Diagnosis Standard applies to urgent referrals for suspected cancer recurrence.

We are developing a Modern Service Framework (MSF) for Palliative Care and End-of-Life Care. The MSF is a clinically led, evidence-based framework to support sustained improvement in outcomes for patients and carers, including by systematically identifying, measuring, and reducing health inequalities, and reducing unwarranted variation in access, experience, and outcomes. Further metrics and associated targets will build on the 2029 ambitions set out in the Neighbourhood Health Framework.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of whether NHS England’s diagnostic imaging turnaround time guidance is sufficient to meet the needs of patients with a recognised terminal diagnosis.

Answered by Sharon Hodgson

While no specific assessment has been made of diagnostic imaging turnaround time guidance and the needs of patients with a recognised terminal diagnosis or the impact of separate reporting time standards, the Government is committed to reducing waiting times for all patients and expects providers to communicate findings in a compassionate manner.

NHS England has established diagnostic reporting turnaround time guidance that applies to all patients. For diagnostic imaging tests, including computed tomography and magnetic resonance imaging scans, the guidance states that verified reports should be available within four weeks of image acquisition. Performance against turnaround times is monitored through routine national reporting. In addition, cancer pathways are supported by national cancer waiting time standards, including the Faster Diagnosis Standard, which aims to ensure that patients receive a diagnosis or have cancer ruled out promptly following an urgent suspected cancer referral. The Faster Diagnosis Standard applies to urgent referrals for suspected cancer recurrence.

We are developing a Modern Service Framework (MSF) for Palliative Care and End-of-Life Care. The MSF is a clinically led, evidence-based framework to support sustained improvement in outcomes for patients and carers, including by systematically identifying, measuring, and reducing health inequalities, and reducing unwarranted variation in access, experience, and outcomes. Further metrics and associated targets will build on the 2029 ambitions set out in the Neighbourhood Health Framework.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has made an assessment on the potential impact of introducing specific diagnostic or reporting time standards for patients with a limited or terminal prognosis.

Answered by Sharon Hodgson

While no specific assessment has been made of diagnostic imaging turnaround time guidance and the needs of patients with a recognised terminal diagnosis or the impact of separate reporting time standards, the Government is committed to reducing waiting times for all patients and expects providers to communicate findings in a compassionate manner.

NHS England has established diagnostic reporting turnaround time guidance that applies to all patients. For diagnostic imaging tests, including computed tomography and magnetic resonance imaging scans, the guidance states that verified reports should be available within four weeks of image acquisition. Performance against turnaround times is monitored through routine national reporting. In addition, cancer pathways are supported by national cancer waiting time standards, including the Faster Diagnosis Standard, which aims to ensure that patients receive a diagnosis or have cancer ruled out promptly following an urgent suspected cancer referral. The Faster Diagnosis Standard applies to urgent referrals for suspected cancer recurrence.

We are developing a Modern Service Framework (MSF) for Palliative Care and End-of-Life Care. The MSF is a clinically led, evidence-based framework to support sustained improvement in outcomes for patients and carers, including by systematically identifying, measuring, and reducing health inequalities, and reducing unwarranted variation in access, experience, and outcomes. Further metrics and associated targets will build on the 2029 ambitions set out in the Neighbourhood Health Framework.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the level of need for NHS health professionals to ask about children’s screen use and social media exposure during routine case histories; and whether guidance will be issued to support clinicians, including newly qualified speech and language therapists, in distinguishing between screen-related language delay and Developmental Language Disorder.

Answered by Sharon Hodgson

The Department recognises the issue of children’s screen use and social media exposure, and the role National Health Service professionals can play.

Screen use guidance forms a core part of the Government’s response to online harms, complementing regulatory action by providing clear, practical advice to parents on supporting safe, balanced, and developmentally appropriate use of digital technologies.

On 27 March 2026, the Government published advice for parents and carers on screen use for children aged zero to five years old on the Best Start in Life website, at the following link:

https://beststartinlife.gov.uk/screen-time-under-5s

This advice offers practical, non-judgemental support to help families balance screen use with other activities. The Children of the 2020s study found that children with the highest screen use at age two, around five hours daily, can say significantly fewer words than those with lower use, although this does not necessarily mean that one causes the other. We are taking a precautionary approach to screen use for younger children, especially where screen time may be replacing activities like moving, sleeping, and playing, which are all important for children’s health and development.

Building on the guidance for zero to five year olds, the Department of Health and Social Care is now working closely with the Department for Education to develop further parent and carer facing guidance for five to 16-year-olds to promote safe and healthy engagement with the digital world. Following the closure of our call for evidence on 29 June, we are reviewing the evidence received to inform the guidance, due to be published this autumn. This work is also being informed by an independent Expert Advisory Group, co-chaired by Children’s Commissioner Dame Rachel de Souza and Professor Russell Viner.

The Department of Health and Social Care is also working closely with the Department for Science, Innovation and Technology on the Government’s media literacy action plan, and we will explore how we can distribute useful information about screen use and social media to relevant clinical and public health networks.

The NHS does not currently have a specific requirement for NHS clinicians to routinely ask about children’s screen use or social media exposure. Clinicians, including speech and language therapists, take a holistic developmental history, considering a range of environmental factors where clinically relevant in order to determine a course of treatment. Clinicians are expected to draw on existing evidence, professional training, and clinical judgement in the assessment of healthcare needs.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, further to the Answer of 16 June 2026 to Question 8929, if his Department will consult with civil society organisations with expertise relating to rare and less survivable cancers when developing the cancer manuals in order to ensure that they fulfil the National Cancer Plan's aim of reducing disparities in cancer survival.

Answered by Sharon Hodgson

The Department and NHS England continue to work with cancer stakeholders on the implementation of the National Cancer Plan and will discuss the development of cancer manuals with relevant stakeholders.

As set out in our National Cancer Plan, the first wave of manuals will include an equal balance of rare cancers, where survival has been slowest, and the most common cancers. It is in the combination of both points that we will maximise progress against our ambition to reduce disparities in cancer survival.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of increasing the level of workforce understanding of endometriosis.

Answered by Sharon Hodgson

The Government acknowledges the challenges faced by women with endometriosis and the impact it can have on their lives, relationships, education, and participation in the workforce. We also recognise the importance of ensuring healthcare professionals are appropriately trained and informed about women’s health conditions, including endometriosis.

The General Medical Council has introduced the Medical Licensing Assessment to encourage a better understanding of common women’s health problems among doctors as they start their careers in the United Kingdom. The content for this assessment includes topics relating to women’s health, including endometriosis.

Women’s health is also included within the Royal College of General Practitioners (RCGP) curriculum for trainee general practitioners (GPs), including gynaecology, sexual health, and breast health. The curriculum also covers the health care needs of women across all diseases seen in primary care as it is important women are treated holistically. This ensures that all future GPs receive education on women’s health.

The RCGP has also published a Women’s Health Library which brings together educational resources and guidance on women’s health from the RCGP, the Royal College of Obstetricians and Gynaecologists, and the College of Sexual and Reproductive Healthcare, supporting healthcare professionals to provide up-to-date care for their patients. The RCGP has worked with partners, including Endometriosis UK, to develop educational resources relating to endometriosis to support GPs and other healthcare professionals to deliver the best possible care for women, based on the latest evidence.

The National Institute for Health and Care Excellence has developed a women’s and reproductive health topic suite, and updated guidelines on endometriosis in 2024 to make firmer recommendations for healthcare professionals on referral and investigations for women with a suspected diagnosis. These clinical guidelines support healthcare professionals in providing care for women with endometriosis.

Generally, employers in the health system are responsible for ensuring that their staff are trained to the required standards to deliver appropriate treatment for patients.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what progress is being made towards establishing Fracture Liaison Services across all NHS trusts by 2030.

Answered by Sharon Hodgson

Our 10-Year Health Plan committed to rolling out Fracture Liaison Services by 2030, and outlines our vision for a more devolved health service.

We are acting across the whole pathway of fracture prevention. This includes improving access to diagnosis, supporting the adoption of effective treatments, and encouraging local systems to develop services that identify people at the highest risk of future fractures and intervene early.

We want integrated care boards (ICBs) to shape services for their localities, and we have set expectations that ICBs will prioritise community-based models when commissioning new services.

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they have commissioned research to establish the rate at which patients treated at adult Gender Dysphoria Clinics subsequently detransition, express regret about their transition, or discontinue treatment.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Cass Review concluded that the percentage of people who subsequently detransition following medical intervention remains unknown due to the lack of long-term follow-up studies.

In response to the recommendations of the Cass Review and the Operational and Delivery Review of Adult Gender Services, NHS England plans to consult on a service specification for a detransition pathway later this year, an element of which will be proposals for building the evidence through data collection, formal research and clinical audit.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 8 October 2025 (HL10538), whether the NHS Supply Chain procurement exercises, including the Total Cardiology and Vascular Solutions Framework, are being developed in line with the draft Value Based Procurement Standard Guidance; and what assessment they have made of whether the evaluation criteria in that guidance include sufficient thresholds for non-price value criteria in particular (1) clinical outcomes, (2) patient quality of life, (3) innovation, (4) sustainability, and (5) whole system efficiencies.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS Supply Chain has worked closely with the Department to support the implementation of its value based procurement (VBP) guidance. Within the Total Cardiology and Vascular Solutions Framework, the Department’s methodology has been piloted on a national procurement and integrated into the non-financial evaluation criteria, with appropriate adaptations made to reflect the specific clinical and operational requirements of the specialty. Value-based assessment criteria and associated non-financial questions have been included where supplier claims can be objectively assessed ensuring a fair, transparent, and equitable evaluation process.

Extensive pre-market engagement was undertaken between March 2025 and September 2025, providing suppliers, customers, clinical associations, and professional bodies with the opportunity to share insights, feedback, and observations on the proposed procurement strategy and overall approach. Communication has been conducted in forms such as team meetings, face to face meetings, and email exchanges with all stakeholders, including clinicians. Draft versions of the VBP questions were circulated during this period to support supplier readiness and to enable meaningful challenge and feedback in advance of tender publication. NHS Supply Chain clinical and category teams engaged extensively with key clinical stakeholder groups, including members of the British Heart Rhythm Society, members of the British Cardiovascular Intervention Society, and NHS England Device Working Groups, to inform the development and refinement of the VBP criteria. The final questions focus on areas where value can be clearly evidenced, including clinical outcomes, innovation, sustainability, social value, and whole-system costs and efficiencies.

While the NHS Supply Chain has successfully incorporated VBP principles into the cardiology and vascular framework evaluation, a key challenge remains the limited availability of standardised Patient Reported Outcome Measures, clinical registries, and other robust outcome datasets to enable consistent and comparable assessment of supplier value claims. Consequently, VBP evaluation has been focused on evidence that can be objectively assessed at the tender stage, with a clear commitment to further validate and measure value throughout the lifetime of the framework as more comprehensive clinical, operational, and patient outcome data becomes available. This approach balances fairness and transparency in procurement with the longer-term ambition of embedding a mature, evidence-based value assessment model across the specialty.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they have taken to seek input from (1) patients, (2) clinicians, (3) medical societies, and (4) suppliers, in the development of the NHS Supply Chain Total Cardiology and Vascular Solutions Framework; and how that input has informed the weighting and clinical assessment of value-based procurement criteria.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS Supply Chain has worked closely with the Department to support the implementation of its value based procurement (VBP) guidance. Within the Total Cardiology and Vascular Solutions Framework, the Department’s methodology has been piloted on a national procurement and integrated into the non-financial evaluation criteria, with appropriate adaptations made to reflect the specific clinical and operational requirements of the specialty. Value-based assessment criteria and associated non-financial questions have been included where supplier claims can be objectively assessed ensuring a fair, transparent, and equitable evaluation process.

Extensive pre-market engagement was undertaken between March 2025 and September 2025, providing suppliers, customers, clinical associations, and professional bodies with the opportunity to share insights, feedback, and observations on the proposed procurement strategy and overall approach. Communication has been conducted in forms such as team meetings, face to face meetings, and email exchanges with all stakeholders, including clinicians. Draft versions of the VBP questions were circulated during this period to support supplier readiness and to enable meaningful challenge and feedback in advance of tender publication. NHS Supply Chain clinical and category teams engaged extensively with key clinical stakeholder groups, including members of the British Heart Rhythm Society, members of the British Cardiovascular Intervention Society, and NHS England Device Working Groups, to inform the development and refinement of the VBP criteria. The final questions focus on areas where value can be clearly evidenced, including clinical outcomes, innovation, sustainability, social value, and whole-system costs and efficiencies.

While the NHS Supply Chain has successfully incorporated VBP principles into the cardiology and vascular framework evaluation, a key challenge remains the limited availability of standardised Patient Reported Outcome Measures, clinical registries, and other robust outcome datasets to enable consistent and comparable assessment of supplier value claims. Consequently, VBP evaluation has been focused on evidence that can be objectively assessed at the tender stage, with a clear commitment to further validate and measure value throughout the lifetime of the framework as more comprehensive clinical, operational, and patient outcome data becomes available. This approach balances fairness and transparency in procurement with the longer-term ambition of embedding a mature, evidence-based value assessment model across the specialty.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to reduce disparities in timely access to diagnostic testing at community-based facilities.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Community diagnostic centres (CDCs) offer patients a wide range of diagnostic tests closer to home and greater choice on where and how they are undertaken, reducing the need for hospital visits and potentially speeding up the start of treatment. CDCs are part of the Government’s aim to shift care out of hospitals and into communities.

NHS England publishes guidance to integrated care boards (ICBs) on CDCs. The 2026 version of the guidance will be published imminently. The guidance sets out the core tests for a CDC. The following table shows the overall type of core diagnostic tests available, as well as the individual modalities:

In addition, the following table shows the overall type of optional diagnostic tests available, as well as the individual modalities:

Data is not collected on timely access to diagnostic services for those from underrepresented groups including women, and those from poorer socioeconomic backgrounds.

One of the central priorities for CDCs is to offer tests for underserved populations. That is why the vast majority of CDCs are located in, or within easy public transport access from, the areas with the most deprivation and health inequalities in each ICB.

Question to the Department of Health and Social Care:

To ask His Majesty's Government which diagnostic tests they require to be available at individual community diagnosis centres.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Community diagnostic centres (CDCs) offer patients a wide range of diagnostic tests closer to home and greater choice on where and how they are undertaken, reducing the need for hospital visits and potentially speeding up the start of treatment. CDCs are part of the Government’s aim to shift care out of hospitals and into communities.

NHS England publishes guidance to integrated care boards (ICBs) on CDCs. The 2026 version of the guidance will be published imminently. The guidance sets out the core tests for a CDC. The following table shows the overall type of core diagnostic tests available, as well as the individual modalities:

In addition, the following table shows the overall type of optional diagnostic tests available, as well as the individual modalities:

Data is not collected on timely access to diagnostic services for those from underrepresented groups including women, and those from poorer socioeconomic backgrounds.

One of the central priorities for CDCs is to offer tests for underserved populations. That is why the vast majority of CDCs are located in, or within easy public transport access from, the areas with the most deprivation and health inequalities in each ICB.

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether directions issued by the Secretary of State to Integrated Care Boards will include measurable outcomes for vaccination programmes such as internationally recognised WHO benchmarks; and how commissioning performance against those outcomes will be assessed.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

From April 2027, integrated care boards (ICBs) will take on responsibility and accountability for commissioning vaccination services. This includes taking on responsibility for improving uptake towards the targets for vaccination coverage which are currently set out as key performance indicators in the National Health Service public health functions agreement 2026 to 2027. These targets will be maintained through delegation.

The NHS Oversight Framework provides a consistent approach to assessing how well providers and ICBs are delivering for patients and supporting improvement. Uptake of the measles, mumps, rubella and varicella vaccine and healthcare worker flu vaccine are included in the metrics used to assess ICB performance. The Department is continuing to develop the detail of our approach to oversight and accountability of the system as part of the transformation to merge NHS England into the Department.

Throughout this period and beyond we will continue to support new vaccination programmes with clear, time-bound delivery plans working with national partners, including the UK Health Security Agency, and partners throughout the system including, from April 2027, offices for pan-ICB commissioning and ICBs.

We will also continue to support commissioners to arrange high-quality vaccination services including supporting a strong core offer through general practice and school-age immunisation services as well as the arrangement of effective supplementary and targeted outreach services that drive uptake where needed and appropriate for population health needs.

Question to the Department of Health and Social Care:

To ask His Majesty's Government how the function currently undertaken by NHS England in collecting and disseminating best practice in vaccination delivery will be maintained under the proposed new commissioning arrangements.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

From April 2027, integrated care boards (ICBs) will take on responsibility and accountability for commissioning vaccination services. This includes taking on responsibility for improving uptake towards the targets for vaccination coverage which are currently set out as key performance indicators in the National Health Service public health functions agreement 2026 to 2027. These targets will be maintained through delegation.

The NHS Oversight Framework provides a consistent approach to assessing how well providers and ICBs are delivering for patients and supporting improvement. Uptake of the measles, mumps, rubella and varicella vaccine and healthcare worker flu vaccine are included in the metrics used to assess ICB performance. The Department is continuing to develop the detail of our approach to oversight and accountability of the system as part of the transformation to merge NHS England into the Department.

Throughout this period and beyond we will continue to support new vaccination programmes with clear, time-bound delivery plans working with national partners, including the UK Health Security Agency, and partners throughout the system including, from April 2027, offices for pan-ICB commissioning and ICBs.

We will also continue to support commissioners to arrange high-quality vaccination services including supporting a strong core offer through general practice and school-age immunisation services as well as the arrangement of effective supplementary and targeted outreach services that drive uptake where needed and appropriate for population health needs.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what plans they have to ensure that newly introduced vaccination programmes are supported by clear, time-bound delivery expectations to enable timely and equitable uptake.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

From April 2027, integrated care boards (ICBs) will take on responsibility and accountability for commissioning vaccination services. This includes taking on responsibility for improving uptake towards the targets for vaccination coverage which are currently set out as key performance indicators in the National Health Service public health functions agreement 2026 to 2027. These targets will be maintained through delegation.

The NHS Oversight Framework provides a consistent approach to assessing how well providers and ICBs are delivering for patients and supporting improvement. Uptake of the measles, mumps, rubella and varicella vaccine and healthcare worker flu vaccine are included in the metrics used to assess ICB performance. The Department is continuing to develop the detail of our approach to oversight and accountability of the system as part of the transformation to merge NHS England into the Department.

Throughout this period and beyond we will continue to support new vaccination programmes with clear, time-bound delivery plans working with national partners, including the UK Health Security Agency, and partners throughout the system including, from April 2027, offices for pan-ICB commissioning and ICBs.

We will also continue to support commissioners to arrange high-quality vaccination services including supporting a strong core offer through general practice and school-age immunisation services as well as the arrangement of effective supplementary and targeted outreach services that drive uptake where needed and appropriate for population health needs.

Question to the Department of Health and Social Care:

To ask His Majesty's Government how many deaths attributable to antibiotic-resistant infections occurred in England in each of the last five years; and of those how many occurred on the NHS estate.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The information requested is not held or routinely published.

The UK Health Security Agency’s (UKHSA) English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) publishes surveillance data on antibiotic-resistant infections, including estimates of 30-day all-cause mortality following resistant bloodstream infections. However, these figures are not a measure of deaths attributable to antimicrobial resistance and should not be interpreted as deaths caused by antibiotic-resistant infections. This surveillance data is available on the GOV.UK website.

The UKHSA publishes case-fatality statistics for healthcare-associated infections, which are available on the GOV.UK website, including methicillin-resistant staphylococcus aureus. However, these cannot be used to determine deaths attributable to antibiotic resistance because they do not distinguish the effect of resistance from other factors such as underlying illness, age, comorbidities, or the infection itself.

There is no breakdown of the statistics by National Health Service estate.

The ESPAUR’s 2024 to 2025 report included a breakdown by hospital- and community-onset infection but did not include place of death and cannot determine the proportion of deaths occurring in hospital.

The UKHSA is now developing the capability to produce annual estimates of deaths attributable to antibiotic-resistant bloodstream infections as part of the United Kingdom’s 2024 to 2029 national action plan for antimicrobial resistance, which is available on the GOV.UK website.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the impact of the 2025 Highly Specialised Technologies routing criteria updates on the number of orphan medicines being diverted to the Standard Technology Appraisal (STA) pathway; and what steps they are taking to ensure that medicines for populations of 300 to 500 patients are not unfairly penalised by lower cost-effectiveness thresholds under the STA route.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Institute for Health and Care Excellence (NICE) highly specialised technologies programme (HST) is reserved for the evaluation of a small number of medicines licensed for the treatment of very rare, very severe diseases. Decisions on whether medicines are routed to the HST programme are taken against a set of published criteria that were updated in April 2025 following public and stakeholder engagement. The purpose of the new criteria is not to change the number or nature of the topics evaluated through the HST programme, but to ensure that the criteria are sufficiently clear and predictable for companies and patient groups and are aligned to the HST vision.

The Government has recently announced a number of pilots and projects following the United States and Untied Kingdom partnership on pharmaceuticals that will shape a commercial environment that actively encourages innovation and improves patient access. As part of that work, NICE will review the approach to valuing rare disease medicines through its Health Technology Assessment Innovation Laboratory. This research will consider both technology appraisal and highly specialised technologies routes. The review will assess a range of both radical and incremental options to improve the current framework.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Statement by Baroness Merron on 2 June (HLWS82), which stated £2.8 million in capital funding will be made available to strengthen and expand provision of focal therapy for prostate cancer, what projects will be funded.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The investment in focal therapies, announced on 2 June 2026, will strengthen existing provision in line with the expansion of the TRANSFORM trial for prostate cancer screening.

Any expansion of focal therapy provision to new sites will include appropriate clinical and market engagement. Officials at the Department are working closely with clinicians and researchers to optimise the planned investment of up to £2.8 million in focal therapy. Further details of this investment will be announced in due course.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what are the financial or legislative barriers to making the display of food hygiene ratings mandatory in England.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Food Standards Agency (FSA) is currently exploring a wide set of reforms to the existing food system, and this will include consideration of a statutory Food Hygiene Rating Scheme in England. As part of this work, the FSA will review the available legislative options and update its assessment of the associated costs and benefits of a statutory scheme. Ministers will consider proposals in due course.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what plans they have to ensure clear accountability for vaccination commissioning and delivery following the withdrawal of Section 7A of the National Health Service Act 2006 and the abolition of NHS England; and what role the Department of Health and Social Care will play in independently evaluating performance across Integrated Care Boards.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

From April 2027, integrated care boards (ICBs) will take on responsibility and accountability for commissioning vaccination services. This includes taking on responsibility for improving uptake towards the targets for vaccination coverage which are currently set out as key performance indicators in the National Health Service public health functions agreement 2026 to 2027. These targets will be maintained through delegation.

The NHS Oversight Framework provides a consistent approach to assessing how well providers and ICBs are delivering for patients and supporting improvement. Uptake of the measles, mumps, rubella and varicella vaccine and healthcare worker flu vaccine are included in the metrics used to assess ICB performance. The Department is continuing to develop the detail of our approach to oversight and accountability of the system as part of the transformation to merge NHS England into the Department.

Throughout this period and beyond we will continue to support new vaccination programmes with clear, time-bound delivery plans working with national partners, including the UK Health Security Agency, and partners throughout the system including, from April 2027, offices for pan-ICB commissioning and ICBs.

We will also continue to support commissioners to arrange high-quality vaccination services including supporting a strong core offer through general practice and school-age immunisation services as well as the arrangement of effective supplementary and targeted outreach services that drive uptake where needed and appropriate for population health needs.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what criteria would trigger the use of powers available to the Secretary of State to intervene in cases of persistent underperformance by Integrated Care Boards; and whether variation in vaccination coverage would form part of that assessment.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

From April 2027, integrated care boards (ICBs) will take on responsibility and accountability for commissioning vaccination services. This includes taking on responsibility for improving uptake towards the targets for vaccination coverage which are currently set out as key performance indicators in the National Health Service public health functions agreement 2026 to 2027. These targets will be maintained through delegation.

The NHS Oversight Framework provides a consistent approach to assessing how well providers and ICBs are delivering for patients and supporting improvement. Uptake of the measles, mumps, rubella and varicella vaccine and healthcare worker flu vaccine are included in the metrics used to assess ICB performance. The Department is continuing to develop the detail of our approach to oversight and accountability of the system as part of the transformation to merge NHS England into the Department.

Throughout this period and beyond we will continue to support new vaccination programmes with clear, time-bound delivery plans working with national partners, including the UK Health Security Agency, and partners throughout the system including, from April 2027, offices for pan-ICB commissioning and ICBs.

We will also continue to support commissioners to arrange high-quality vaccination services including supporting a strong core offer through general practice and school-age immunisation services as well as the arrangement of effective supplementary and targeted outreach services that drive uptake where needed and appropriate for population health needs.

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether any key target been removed from the Modern Service Framework for Dementia and Frailty, due for publication later this year.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

No target has been removed from the Modern Service Framework for Frailty and Dementia. The framework is still in development, and we are still considering all options to help improve dementia diagnosis and care, including reviewing targets, metrics, and data.

We are engaging with a wide group of partners to understand what should be included to ensure the best outcomes for people living with frailty and dementia. As part of this exercise, we will develop a list of best evidenced interventions following analysis of the evidence and wider research.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the impact on patients of increasing wait times for NHS community services.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

We know that people are waiting too long for community services. That is why, for the first time, we have set a clear target for systems to work to reduce long waits. By 2028/29, at least 80% of community health services activity should take place within 18 weeks, bringing community health services in line with targets for elective care.

In 2025, we published Standardising Community Health Services which provides an overview of core community health services. Setting clear expectations of the core community health services, integrated care boards will support consistent delivery of community health services and effective commissioning, and will improve patient access to care.

NHS England works with local systems, including integrated care boards, to manage demand and mitigate the impact of waiting times on patients, particularly in areas of highest clinical risk. Community health services waiting time data is monitored nationally through NHS England's monthly Community Health Services Situation Report.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the impacts of untreated ADHD and neurodivergence.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government is deeply concerned that too many adults, children, and young people with attention deficit hyperactivity disorder (ADHD) and autism are not getting the support they need early enough, consistently enough, or in ways that are well matched to their needs. There is a range of cross-Government work underway that is examining the impacts of neurodevelopmental conditions on health, education, and employment, and how people can be supported earlier and more effectively.

In December 2025, the Government launched an Independent Review into Prevalence and Support for Mental Health Conditions, ADHD and Autism. The final report, due in the summer, will make recommendations on how the Government, the health system, and wider public services can respond to increasing demand for support more fairly and effectively so that people receive the right support, at the right time, in the right place.

We are also committed to transforming outcomes for children, young people, and their families with special educational needs and disabilities (SEND) through pivotal reforms. We want these reforms to support the treatment to prevention shift in our 10-Year Health Plan and its focus on early identification of needs, support, and intervention, enabling more children to access support and thrive in inclusive mainstream settings.

Central to this is the new Experts at Hand offer, backed by £1.8 billion over three years, which will bring health and education professionals around mainstream settings. Alongside this, £1.6 billion will be invested over the next three years to make the mainstream system more inclusive, building on the latest evidence and practice. By 2028, up to £15 million will have been invested to build the evidence base for, and then provide, national inclusion standards. These will set out, for the first time, what support should be available in every mainstream setting. We will also refresh areas of need, update guidance on reasonable adjustments, and revise the SEND Code of Practice.

The Timms Review, the first review of the Personal Independence Payment benefit, is examining how it can better support disabled people to live independently and access the right support at the right level. The review is due to report in the autumn. Additionally, the Milburn Review on Young People and Work is examining how health conditions can affect participation in education, employment, and training, and the implications for welfare dependency. It published its interim report on 28 May, with the final report due to be published later this year.

The Government will consider the findings of these reviews to inform future Government decisions.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to maximise the contribution of dance and the arts to the NHS prevention programme, including through collaboration between the Department for Culture, Media and Sport and the Department of Health and Social Care.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Dance is recognised within the Chief Medical Officer’s Guidelines on Physical Activity as a form of physical activity that can improve health at every stage of the life course. Dance is a broad discipline of creative activity from ballet to street dance, and the evidence of potential health benefits spans informal dancing through structured dance classes to clinical dance therapies.

The Department of Health and Social Care is working with partners including the Department for Culture, Media and Sport, Arts Council England, and the National Centre for Creative Health to understand and develop the evidence base and consider the policy implications for creative health to improve health outcomes and support delivery of the 10-Year Health Plan.

One specific example of the evolving collaboration is that in Spring 2026, NHS South West worked with Let’s Dance and Parkinson’s UK to raise awareness of the evidence of impact of dance on both physical and mental health symptoms of Parkinson’s disease through targeted amplification of the national Let’s Dance campaign to patients and clinicians. This work was amplified nationally, and further work is being take forward to explore further scaling for the 2027 Let’s Dance campaign.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the remarks by Baroness Merron on 15 April (HL Deb, cols 27GC-28GC), what consideration they have given to exempting the provision of treatment to those in the performing arts, elite athletes, and their teams, from the list of regulated activities for the purposes of the Health and Social Care Act 2008.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government has heard from a range of industry and medical stakeholders and will consider the range of views provided in relation to potential exemptions. There will be close liaison with the Care Quality Commission (CQC) to ensure that everyone either participating in or attending cultural or sporting events receive safe and effective care. The CQC continues to engage with providers to ensure minimal impact on them whilst achieving those aims.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the role of dance and the wider cultural sector in improving public health outcomes and reducing health inequalities; and what discussions they have had across government departments on this topic.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department of Health and Social Care is working with partners including the Department for Culture, Media and Sport, Arts Council England, and the National Centre for Creative Health to understand and develop the evidence base and consider the policy implications.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what role they intend Best Start Family Hubs to play in identifying and supporting mothers experiencing perinatal and postnatal mental health difficulties.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Supporting perinatal mental health and parent-infant relationships are vital to the health and wellbeing of babies and their caregivers.

The Department is investing £200 million for Healthy Babies services in 75 local authority areas with high levels of deprivation, including £109 million to provide enhanced parent-infant relationship and perinatal mental health support. This forms part of a £900 million package in Best Start Family Hubs and Healthy Babies to create a more integrated, accessible system of support for families.

All Best Start Family Hubs should provide safe and inclusive perinatal mental health support, identifying needs early, offering emotional support and help families to access appropriate support and services within their local area. Healthy Babies funded areas are expected to deliver an enhanced perinatal mental health service, with proactive identification, accessible support, and clear referral pathways. These services complement National Health Service provision for parents with moderate to severe perinatal mental health needs.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the total economic costs of ADHD and neurodivergence; and what assessment they have made of how this cost could be addressed through improved treatment.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government itself has not made an overall economic assessment of the impact of attention deficit hyperactivity disorder (ADHD) and neurodivergence. However, the independent ADHD Taskforce, which reported in 2025, reported that currently the estimated economic costs of not treating ADHD are approximately £17 billion to the United Kingdom’s economy. Three relevant ongoing reviews will help the Government better understand the issues and how they could be addressed.

The Government announced on 4 December 2025 the launch of an Independent Review into Prevalence and Support for Mental Health Conditions, ADHD and Autism. The final report, due in the summer, will make recommendations on how the Government, the health system, and wider public services can respond to increasing demand for support more fairly and effectively so that people receive the right support, at the right time, in the right place.

The next stage of the review will look at service design and how services might respond more effectively to rising need, including the role of earlier intervention, community-based provision, and more integrated pathways across health, education, and other public services. The review will also look at the question of what role the private sector plays in diagnostic services.

The Timms Review, the first review of the Personal Independence Payment benefit, is examining how it can better support disabled people to live independently and access the right support at the right level. It published its interim report on 15 July 2026, with the final review due to report in the autumn. Additionally, the Milburn Review on Young People and Work is examining how health conditions, including ADHD and autism, can affect participation in education, employment, and training, and the implications for welfare dependency. It published its interim report on 28 May, with the final report due to be published later this year. The Government will consider the findings from these reviews, alongside those of the Independent Review into Prevalence and Support for Mental Health Conditions, ADHD and Autism.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the UK's fall in ranking from fifth to eleventh between 2020 and 2025 in the EFPIA Waiting to Access Innovative Therapies Indicator for orphan medicine availability; and what steps they are taking to ensure the UK remains a priority 'first-launch' market for global biotechnology firms.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

No specific assessment has been made. The Government recognises how important it is that patients with rare diseases are able to benefit from access to effective new medicines. The National Institute for Health and Care Excellence (NICE) has a strong track record in supporting access to new medicines for patients with rare diseases with 89% of the rare disease medicines that it has appraised since March 2024 recommended for some or all of the eligible patient population.

Through the Life Sciences Sector Plan and the 10-Year Health Plan, we are taking steps to make the United Kingdom a faster place to approve and adopt new medicines. This includes wider use of real-world evidence, more flexible commercial deals, faster NICE guidance, and a new joint NICE and Medicines and Healthcare products Regulatory Agency pathway to shorten the time from approval to National Health Service use.

We recognise that there is more to do to improve and accelerate access to new medicines for NHS patients and the steps that we are taking as part of the pharmaceuticals partnership with the United States are already resulting in medicines, including medicines for patients with rare diseases, becoming available to NHS patients that may not otherwise have been recommended.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the remarks by Baroness Merron on 15 April (HL Deb, cols 27GC–28GC), whether they intend the provision of treatment by foreign medical teams to those in the performing arts, elite athletes, and their teams, temporarily visiting the UK to constitute a “regulated activity” for the purposes of the Health and Social Care Act 2008 upon the coming into force of regulation two of the Health and Social Care Act 2008 (Regulated Activities) (Amendment) Regulations 2026 (SI 2026/495); and if not, what assessment they have made of the implications of any difference in requirements for foreign and domestic medical staff.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Care Quality Commission (CQC) is the regulator for health and social care in England. Providers of health and adult social care who are wholly based outside England would typically not register with the CQC.

This is because the CQC does not hold jurisdiction to regulate providers outside England and therefore cannot inspect and take enforcement action against them if the service being provided fails to meet the necessary standards as set out in the regulations.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the remarks by Baroness Merron on 15 April (HL Deb, cols 27GC–28GC), whether they consider that the Care Quality Commission has the requisite (1) knowledge, and (2) financial resources, to regulate the provision of treatment to those in the performing arts, elite athletes, and their teams.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Care Quality Commission (CQC) regulates the treatment of disease, disorder, and injury across a range of industries, which includes pre-hospital care. The CQC continues to engage with providers of event healthcare directly, and has worked with the Government to meet with industry and medical leaders. This engagement continues.

In accordance with its normal ways of working, the CQC will recruit a team of specialist advisors who are experts in their field to join the inspections of providers. The purpose of that inclusion is to ensure that all regulatory decisions are based upon current best practice. The CQC continues to monitor the implementation of the review of regulations to ensure that financial matters have due attention.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the answer by Baroness Merron on 6 July (HL Deb col 2), how many Integrated Care Boards (ICBs) do not have a fracture liaison service in each of the NHS hospitals within the ICB.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Analysis of 2025 Fracture Liaison Services (FLS) data shows that the number of FLS’ in England has increased since 2024, from 80 to 83. These 83 services are based in 23 out of the 25 integrated care board (ICB) clusters.

Analysis of the 2025 data suggests that no ICB clusters had an FLS in each of the NHS hospitals within the ICB clusters. The number of FLS’ per ICB cluster ranged from one to eight.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what data they collect on timely access to diagnostic services for those from underrepresented groups including (1) women, and (2) those from poorer socioeconomic backgrounds.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Community diagnostic centres (CDCs) offer patients a wide range of diagnostic tests closer to home and greater choice on where and how they are undertaken, reducing the need for hospital visits and potentially speeding up the start of treatment. CDCs are part of the Government’s aim to shift care out of hospitals and into communities.

NHS England publishes guidance to integrated care boards (ICBs) on CDCs. The 2026 version of the guidance will be published imminently. The guidance sets out the core tests for a CDC. The following table shows the overall type of core diagnostic tests available, as well as the individual modalities:

In addition, the following table shows the overall type of optional diagnostic tests available, as well as the individual modalities:

Data is not collected on timely access to diagnostic services for those from underrepresented groups including women, and those from poorer socioeconomic backgrounds.

One of the central priorities for CDCs is to offer tests for underserved populations. That is why the vast majority of CDCs are located in, or within easy public transport access from, the areas with the most deprivation and health inequalities in each ICB.

Question to the Department of Health and Social Care:

To ask His Majesty's Government when NHS England's evidence review of hormone treatment for adults with gender dysphoria will be published; and whether the NHS service specification on gender identity services for adults will be revised in the light of the findings of the review before any new services are commissioned.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England plans to publish proposed clinical commissioning policies for the use of masculinising and feminising hormones in adult gender services later in the summer, for the purpose of public consultation. Separately, NHS England plans to publish new service specifications for adult gender services, for the purpose of public consultation, later this year.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 29 April (HL16567), whether the National Consultant Information Programme (1) is publicly accessible to patients, (2) includes data on consultants practising in the independent sector, and (3) records the practising privileges held by consultants; and what assessment they have made of that Programme's compliance with the Paterson Inquiry's recommendation for a single repository of information about consultants across England.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Consultant Information Programme (NCIP) is publicly accessible to patients on the Getting It Right First Time website.

The NCIP portal is a free data platform containing consultant and provider-level activity and outcomes data for over 500 procedures in 13 surgical specialties. It covers National Health Service practices, NHS funded work in the independent sector, and privately funded work carried out in the NHS. Over time, the ambition is to add independent sector data, to provide a single repository of whole practice. Currently, patients are not able to access this data.

NCIP allows consultants in 13 surgical specialties to access their individual outcomes data, for personal learning, clinical governance, and appraisals. NCIP does not record practising privileges in the independent sector.

NCIP is a critical part of the response to the Paterson Inquiry, which recommended that there should be a single repository of the whole practice of consultants across England. By sharing high-quality outcome data, consultants, their appraisers, and responsible officers can compare outcomes for their practice or use peer review to improve their performance in a way that is measurable and objective, leading to better safety and efficiency across the NHS.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 6 July (HL1488), how the Medicines and Healthcare products Regulatory Agency will communicate the conclusions of its review of mental health risks for migraine prophylaxis medications; whether that Agency will consider a drug safety update or other national safety communication; and whether any resulting changes to product information would be reflected in national electronic prescribing and medicines decision-support systems.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department with responsibility for ensuring medicines meet appropriate standards of quality, efficacy, and safety.

The MHRA has plans to gather the currently available evidence on mental health and other related risks for licensed migraine prophylaxis medications, as referenced in the separate responses to questions HL1488 and HL1543. A formal timeline for this review has not yet been agreed, and consequently we are unable to provide an expected completion date at this stage.

The MHRA is committed to communicating any findings that may have implications for patient safety or the safe use of medicines. The MHRA will sometimes issue communications, such as drug safety updates, after the conclusion of a review. However, the review is at an early stage, and it would be premature to comment on any potential communication plans. In addition, any product information changes that may arise as a result of this review would be reflected in the published product information available at locations such as the MHRA website or the Electronic Medicines Compendium website.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 6 July (HL1488), when they expect the Medicines and Healthcare products Regulatory Agency to complete its review of evidence on mental health and related risks for licensed migraine prophylaxis medications.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department with responsibility for ensuring medicines meet appropriate standards of quality, efficacy, and safety.

The MHRA has plans to gather the currently available evidence on mental health and other related risks for licensed migraine prophylaxis medications, as referenced in the separate responses to questions HL1488 and HL1543. A formal timeline for this review has not yet been agreed, and consequently we are unable to provide an expected completion date at this stage.

The MHRA is committed to communicating any findings that may have implications for patient safety or the safe use of medicines. The MHRA will sometimes issue communications, such as drug safety updates, after the conclusion of a review. However, the review is at an early stage, and it would be premature to comment on any potential communication plans. In addition, any product information changes that may arise as a result of this review would be reflected in the published product information available at locations such as the MHRA website or the Electronic Medicines Compendium website.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what plans they have to assess the impact of obesity treatment on economic inactivity and workforce participation.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government recognises that obesity is associated with significant labour market challenges, including reduced workforce participation and increased sickness absence. The Government remains committed to monitoring emerging evidence to better understand the full range of health and economic benefits associated with obesity treatments. Indeed, the evidence base for the impact of health interventions on employment outcomes is rapidly growing, with very robust evidence on the impact of bariatric surgery and Talking Therapies.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the equality impact assessment Health Bill: ICBs as strategic commissioners, published on 14 May, what mechanisms they intend to use to ensure enhanced oversight of Integrated Care Board specialised commissioning.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Subject to the passage of the Health Bill, specialised services commissioned by integrated care boards (ICBs) will continue to operate within a framework of nationally-set standards, service specifications, and clinical commissioning policies to ensure consistent and equitable access to care across England.

Alongside ICB accountability for commissioning these services, the Department, through its new regional offices, will be responsible for providing oversight and assurance of both the commissioning system and the quality and performance of providers. This will include monitoring against national standards and quality and outcome metrics for different services.

In addition, ICBs will be supported in discharging their new commissioning responsibilities through seven Offices for Pan-ICB Commissioning, which aim to ensure that we maintain a critical mass of expert commissioning knowledge and the capability necessary for the effective and efficient commissioning of these important and complex areas of service provision.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what guidance they have issued to Integrated Care Boards on the allocation of resources towards prevention, primary care, and community services.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England is responsible for determining allocations of financial resources to integrated care boards (ICBs). NHS England’s allocations policy aims to support equal opportunity of access for equal need, as well as NHS England’s duties to reduce health inequalities that are amenable to healthcare.

The Medium Term Planning Framework sets out the priority deliverables and the reform opportunities that ICBs and providers need to deliver for the next three years and the broader strategic aims that will need to be reflected in five year plans developed by each organisation. This includes expectations on prevention, and on neighbourhood health, including primary and community care. Further guidance on neighbourhood health has also been set out in the subsequent Neighbourhood health framework.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what safeguards they will put in place to ensure that decisions relating to public health functions continue to be informed by appropriate expert consultation following the removal of the statutory duty previously held by NHS England.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Following the abolition of NHS England, my Rt Hon. Friend, the Secretary of State for Health and Social Care, will continue, where appropriate, to obtain public health expert advice and to utilise the best evidence to inform decisions, in accordance with the Ministerial Code. This will include seeking expert advice from committees, such as the Joint Committee on Vaccination and Immunisation, organisations including the UK Health Security Agency, or individuals such as the Chief Medical Officer.

Integrated care boards’ existing duty to obtain appropriate advice on the prevention, diagnosis, or treatment of illness and the protection or improvement of the public’s health will be retained.

Question to the Department of Health and Social Care:

To ask His Majesty's Government how many cyber incidents the NHS Cyber Security Operations Centre (1) detected and prevented, (2) detected but failed to prevent, and (3) initially detected but subsequently found to be a false alarm, in (a) the first half of 2025, (b) the second half of 2025, and (c) the first half of 2026.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The following figures are from the NHS England Cyber Security Operations Centre (CSOC) incident ticketing systems, namely aggregating data from security tooling that monitors cyber security incidents detected by, or reported to, the CSOC. The following table shows the number of security incidents detected by the CSOC where the impact to National Health Services has been prevented:

There are no recorded cyber security incidents that were initially detected by the CSOC which were subsequently not prevented.

The following table shows the number of security incidents initially detected by CSOC security tooling, but which were subsequently found to be a false alarm via either automated mechanisms or manual activity:

As these are false positives, the data surrounding them is only retained for 12 months, making a response to 2025H1 not possible.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what is the pathway to treatment for a patient diagnosed with osteoporosis.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

We would expect healthcare professionals to follow the National Institute for Health and Care Excellence (NICE) clinical knowledge summary on osteoporosis and the prevention of fragility fractures. The clinical knowledge summary outlines the steps that healthcare professionals should take in the assessment and management of osteoporosis.

A diagnosis of osteoporosis is made following clinical assessment and in some cases by use of blood tests and DEXA scans. The National Health Service does not provide universal osteoporosis screening, instead, a targeted approach is used to identify those most likely to benefit from assessment and treatment. Tools like FRAX are recommended to calculate 10-year fracture risk and guide clinical decisions. A DEXA scan can also be used to measure bone mineral density.

There are a number of NICE recommended treatments for osteoporosis. Since 2022, two new drugs have been recommended by NICE for the treatment of osteoporosis in post-menopausal women, abaloparatide and romosozumab. These medications help to strengthen the bones and prevent bone loss, reducing the risk of fractures.

Found: This summer, for the first time, DHSC and DfE will provide agreed wording that schools can use in their

Found: Hodgson MP Parliamentary Under-Secretary of State for Public Health and Prevention Department of Health and Social Care

Found: departmental Chief Scientific Advisers Professor Lucy Chappell, Chief Scientific Adviser, Department of Health and Social Care

Found: , such as the defence investment plan and the reforms that the Cabinet Office, the Department of Health and Social Care

Question to the Department for Education:

To ask His Majesty's Government how they consult health professionals on the health implications for pupils of the use of screen-based devices and educational technology applications in schools in England; and which committees, working groups or advisory bodies they maintain for that purpose.

Answered by Baroness Smith of Malvern - Minister of State (Department for Work and Pensions)

The department works closely with the Department of Health and Social Care, including on regular policy and evidence exchanges on the implications of screen-based devices and education technology for pupils. This includes drawing on medical and child development expertise, and wider evidence on children’s health, wellbeing and learning.

The department established expert arrangements to inform its work on screen use, including an expert group co-chaired by the Children’s Commissioner for England and Professor Russell Viner to support evidence-based guidance for children and families.

The department has also launched a Call for Evidence on screen use for children aged 5 to 18 and exploring how to support schools and families to make informed, evidence-based decisions about technology use.

Schools are expected to use technology in a safe, proportionate and purposeful way, alongside statutory safeguarding duties, filtering and monitoring requirements, and statutory guidance that schools should be mobile phone-free environments by default.

Question to the Ministry of Justice:

To ask His Majesty's Government what record is made at each stage of the criminal justice system of whether an individual has ADHD or another neurodevelopmental condition; and whether that record is linked to health, education, or employment records.

Answered by Baroness Levitt

The Ministry of Justice is committed to improving support for neurodivergent individuals, including those with ADHD, across the criminal justice system.

We recognise the importance of early identification of individuals’ needs. As part of the Neurodiversity Action Plan, HMCTS has developed a signposting strategy to help court and tribunal users with additional needs to access support. HMPPS take a needs-led approach to supporting neurodivergent individuals and now screens all prisoners upon arrival. It has introduced a new Additional Learning Needs screener as part of the new Prisoner Education Service. This allows HMPPS to identify any needs and inform appropriate support and reasonable adjustments in order to help prisoners engage with education, skills, work and rehabilitation opportunities.

We continue to work with partners, including the Department of Health and Social Care (DHSC) through the Health and Justice National Neurodiversity Programme Board, building on progress highlighted in the final update to the Cross-Government Neurodiversity Action Plan, published in February 2026. Our approach draws on the wider recommendations of NHS England's Independent ADHD taskforce and the Chief Medical officer's report on the health of people in prison and on probation, which included a focus on neurodiversity. We have no current plans to establish a separate Taskforce.

Question to the Ministry of Justice:

To ask His Majesty's Government what plans they have to create a dedicated taskforce to transform how ADHD and neurodivergence are supported across the criminal justice system.

Answered by Baroness Levitt

The Ministry of Justice is committed to improving support for neurodivergent individuals, including those with ADHD, across the criminal justice system.

We recognise the importance of early identification of individuals’ needs. As part of the Neurodiversity Action Plan, HMCTS has developed a signposting strategy to help court and tribunal users with additional needs to access support. HMPPS take a needs-led approach to supporting neurodivergent individuals and now screens all prisoners upon arrival. It has introduced a new Additional Learning Needs screener as part of the new Prisoner Education Service. This allows HMPPS to identify any needs and inform appropriate support and reasonable adjustments in order to help prisoners engage with education, skills, work and rehabilitation opportunities.

We continue to work with partners, including the Department of Health and Social Care (DHSC) through the Health and Justice National Neurodiversity Programme Board, building on progress highlighted in the final update to the Cross-Government Neurodiversity Action Plan, published in February 2026. Our approach draws on the wider recommendations of NHS England's Independent ADHD taskforce and the Chief Medical officer's report on the health of people in prison and on probation, which included a focus on neurodiversity. We have no current plans to establish a separate Taskforce.

Found: briefing on Early medical abortion at home during and after the pandemic. 6 Department of Health and Social Care

Found: can include the NHS, integrated care systems, and other bodies approved by local authorities or the DHSC

Found: /nhs-procurementtogether with any further Guidance issued from time to time by the Department of Health and Social Care

Found: nhs-procurement together with any further Guidance issued from time to time by the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: urgent medical treatment in the UK following agreement about such treatment with the Department of Health and Social Care

Found: for Education - SME Action Plan Department for Business and Trade - SME Action Plan Department of Health and Social Care

Found: However, as a proportion of total Health & Social Care contracts, DHSC only awarded 25% of the total

Found: DHSC recognises the value in keeping the arrangements for health data in the Digital Economy Act 2017

Found: DHSC recognises the value in keeping the arrangements for health data in the Digital Economy Act 2017

Found: Page Seventy-sixth report: New Hospital Programme update 2 Department of Health and Social Care

Found: Page Seventy-sixth report: New Hospital Programme update 2 Department of Health and Social Care

Found: Page Seventy-sixth report: New Hospital Programme update 2 Department of Health and Social Care

Found: Page Seventy-sixth report: New Hospital Programme update 2 Department of Health and Social Care

Found: The Department of Health and Social Care (DHSC) is exploring whether to refresh guidance on the working

Found: These are: Department for Culture, Media and Sport, Department of Health and Social Care, Department

Found: Both the Department of Health and Social Care and the Welsh Government are currently unable to report

Found: Department / body Annual Statement for Research Integrity 2025-26 Department for Health and Social Care DHSC

Found: Department / body Annual Statement for Research Integrity 2025-26 Department for Health and Social Care DHSC

Found: Supported by the Department of Health and Social Care (DHSC) and the Regulatory Innovation Office (RIO

Found: nhs-procurement together with any further Guidance issued from time to time by the Department of Health and Social Care

Found: /nhs-procurementtogether with any further Guidance issued from time to time by the Department of Health and Social Care

Found: The MHRA is an executive agency of the Department of Health and Social Care.  

Found: The MHRA is an executive agency of the Department of Health and Social Care.  

Found: for Work and Pensions Rt Hon Dame Diana Johnson DBE MP as Minister of State in the Department of Health and Social Care

Found: for Work and Pensions Rt Hon Dame Diana Johnson DBE MP as Minister of State in the Department of Health and Social Care

Found: for Work and Pensions Rt Hon Dame Diana Johnson DBE MP as Minister of State in the Department of Health and Social Care

Found: The MHRA is an executive agency of the Department of Health and Social Care.   

Found: The MHRA, in discussion with the Department of Health and Social Care, considers these products critical

Found: The survey was led by the Office for Health Improvement and Disparities, part of the Department of Health and Social Care

Found: general-medical-services- statement-of-financial-entitlements-directions or from the Primary Care Team, Department of Health and Social Care

Found: have been notified to the Contractor by the Commissioner, NHS England and/or the Department of Health and Social Care

Found: general-medical-services- statement-of-financial-entitlements-directions or from the Primary Care Team, Department of Health and Social Care

Found: Hard copies are available from the Department of Health and Social Care, 39 Victoria Street, London,

Found: (DHSC).

Found: In an MPF scenario, the Department of Health and Social Care (DHSC) would also activate robust, sector‑wide

Found: (DHSC) ..................................................... 9 4.8 Ministry of

Found: The Department of Health and Social Care (DHSC) is exploring whether to refresh guidance on the working

Found: [Extract from BCAM consolidated response to DHSC consultation on regulation of non- surgical procedures0

Found: Beauty, Aesthetics and Wellbeing – What is the concern call for evidence • BACN Response to the DHSC

Found: [Extract from BCAM consolidated response to DHSC consultation on regulation of non- surgical procedures0

Found: Beauty, Aesthetics and Wellbeing – What is the concern call for evidence • BACN Response to the DHSC

Found: From recent statements that Ministers within the Department of Health and Social Care have given, we

Found: WWW.COSMETICSTANDARDS.ORG.UK/UPLOADS/1/0/6/2/106271141/20180103_CPSA_SUPERVISION_MATRIX_FINAL.PDF • DEPARTMENT OF HEALTH AND SOCIAL CARE